Anthem Biosciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.74×	0.72×
	1.19×	1.18×
	32.7%	32.9%
	0.62×	0.62×
	1.13×	1.13×
	20.1%	19.5%
	19.5%	19.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ANTHEM₹805.70

Anthem Biosciences Ltd.

· Pharma & Health

₹ CrorePeersSYNGENE DIVISLAB GLAXO AJANTPHARM IPCALAB ABBOTINDIA MEDANTA GLENMARKMcap ₹45,257 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.72	0.74
Interest Burden (Pretax/EBIT) ×	1.18	1.19
EBIT Margin %	32.94	32.73
Asset Turnover ×	0.62	0.62
Financial Leverage (Assets/Equity) ×	1.13	1.13
ROE (5-step product, year-end total equity) %	19.47	20.10
ROE (owners' profit / average owners' equity) %	19.45	19.45

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.